UNSPSC 51142314: Nalorphine hydrochloride

This classification denotes an opioid receptor agonist with the molecular formula C19H21NO3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9FPE56Z2TW, chemically known as 17-allyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6alpha-diol hydrochloride but more generally known as nalorphine hydrochloride, which bears US NIH Compound Identifier 5484366. European Medicines Agency schedules Nalorphine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03381MIG.

UNSPSC 51142314 Nalorphine hydrochloride is a Commodity code representing opioid antagonist and narcotic antagonist medications purchased by state and local health agencies to support emergency response, addiction treatment, and community health initiatives. State and local governments soliciting under this code include county health departments, state health and human services commissions, and cooperative purchasing alliances serving multiple jurisdictions. The work involves procurement of naloxone (the primary active ingredient in commercially available opioid reversal products) and related drug deactivation systems, typically for distribution through community health facilities, emergency services, or pharmacy benefit programs. Quantities range from hundreds to thousands of units annually, with deliveries structured on regular schedules—quarterly in some cases—to support ongoing operational needs rather than one-time capital purchases.

Recent activity shows solicitation by Seminole County, Florida, which issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, which issued an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products with a due date of March 26, 2026, covering participating state and local facilities in Minnesota and Oregon; and the Texas Health and Human Services Commission, which issued an RFI in April 2026 to explore direct-to-manufacturer prescription fulfillment models. The geographic spread encompasses Florida, Texas, Minnesota, and Oregon, with activity driven primarily by county health systems and state cooperative purchasing vehicles rather than isolated municipal procurement. Vendors pursuing this code should expect requirements for cGMP and Drug Supply Chain Security Act compliance, established relationships with authorized pharmaceutical wholesalers, comprehensive insurance coverage, E-Verify employment verification, and adherence to both state and federal regulatory frameworks when FEMA or similar federal funding is involved.